Delving into the Latest Updates on Datopotamab Deruxtecan with Synapse

The researchers are doing this study to find out whether ivonescimab in combination with datopotamab deruxtecan- (Dato-DXd) or osimertinib are safe and effective treatments in people with non-small cell lung cancer (NSCLC) that has an EGFR mutation. The researchers will test different doses of the Dato-DXd or osimertinib with an unchanging (fixed) dose of ivonescimab to find the best dose that causes few or mild side effects in participants. Once the dose is found the researchers will test ivonescimab with Dato-DXd or osimertinib in a new group of participants to see if it is effective in treating their NSCLC with an EGFR mutation.

Start Date09 Apr 2026

Sponsor / Collaborator

Memorial Sloan Kettering Cancer Center

[+1]

NCT07471776

/ RecruitingPhase 2IIT

Study on Using TROP2-PET and 18F-FDG PET to Predict the Efficacy of Anti TROP2 ADC Treatment in Advanced Breast Cancer

This study aims to evaluate whether ^68Ga-TROP2 PET/CT, combined with ^18F-FDG PET/CT, can predict the efficacy of anti-TROP2 antibody-drug conjugates in patients with advanced HER2-negative breast cancer. Baseline and dynamic imaging parameters will be used to develop prediction models (primary endpoint: AUC), and their associations with clinical outcomes and tumor TROP2 status will be explored.

Start Date11 Mar 2026

Sponsor / Collaborator

Fudan University

NCT07357597

/ Not yet recruitingPhase 4

A Phase IV, Open-Label, Single-Arm Study of Prophylaxis for Datopotamab Deruxtecan-related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer (TROPION-SWISH)

This is a multicenter, open-label, single-arm study of prophylaxis for Dato-DXd-related stomatitis in eligible patients with metastatic or inoperable locally recurrent breast cancer or locally advanced or metastatic Epidermal Growth Factor Receptor-Mutated (EGFRm) non-small cell lung cancer.

Start Date27 Feb 2026

Sponsor / Collaborator

AstraZeneca PLC

[+1]

100 Clinical Results associated with Datopotamab Deruxtecan

Login to view more data

100 Translational Medicine associated with Datopotamab Deruxtecan

Login to view more data

100 Patents (Medical) associated with Datopotamab Deruxtecan

Login to view more data

118

Literatures (Medical) associated with Datopotamab Deruxtecan

01 May 2026·CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Resistance mechanisms and post-trastuzumab deruxtecan (T-DXd) strategies in HER2+ and HER2-low breast cancer: From biology to clinical practice

Review

Author: Xue, Wenwu ; Chen, Minna ; Wen, Xiaofen ; Li, Xiaozhi ; Zeng, De ; Song, Junwei ; Lin, Danxia ; Wang, Wende ; Zhang, Weichun ; Shen, Jiaxin

Trastuzumab deruxtecan (T-DXd), a HER2-directed antibody-drug conjugate (ADC), has revolutionized the treatment landscape for HER2-positive and HER2-low breast cancer, offering unprecedented improvements in progression-free survival (PFS) and overall survival (OS). However, the emergence of resistance limits its long-term efficacy and highlights the need for rational post-progression strategies. This review summarizes current understanding of resistance mechanisms to T-DXd, including dynamic HER2 expression loss, dysregulation of DNA damage repair, tumor microenvironment remodeling, and immune evasion. Building upon these mechanistic insights, we explore therapeutic strategies following T-DXd resistance, including sequential ADCs with alternative targets or payloads, combinations with HER2-targeted tyrosine kinase inhibitors (TKIs), CDK4/6 or PARP inhibitors, endocrine therapy, and immunotherapy. Novel agents such as ARX788, patritumab deruxtecan, and Dato-DXd demonstrate promise in overcoming resistance through diversified mechanisms. Real-world data further support a "three-step strategy" involving ADC rechallenge after interim non-ADC therapies, offering a practical, mechanism-informed treatment model. This review provides a framework for precision-guided care in patients with advanced breast cancer and supports ongoing efforts to extend the therapeutic window beyond initial T-DXd benefit.

01 Mar 2026·ANNALS OF ONCOLOGY

Osimertinib plus datopotamab deruxtecan in patients with EGFR-mutated advanced NSCLC after progression on first-line osimertinib: ORCHARD

Article

Author: Halvorsen, T O ; Morabito, A ; Ambrose, H ; Yu, H A ; Cho, B C ; Brustugun, O T ; Goldman, J W ; Marrone, K A ; Bonanno, L ; Shiraishi, Y ; Piotrowska, Z ; FraenkeI, P G ; Hendriks, L E L ; Kim, Y J ; Riess, J W ; Le, X ; Smith, P E ; Tang, K H ; de Langen, A J ; Lehman, J M ; Goldberg, S B

BACKGROUND:

ORCHARD (NCT03944772) was a phase II platform study conducted to characterize resistance mechanisms and evaluate novel treatment combinations following progressive disease (PD) on first-line osimertinib. Datopotamab deruxtecan (Dato-DXd) is an anti-TROP2 antibody-drug conjugate approved as monotherapy in EGFR-mutated advanced non-small-cell lung cancer (NSCLC). We report final data from the osimertinib plus Dato-DXd module.

METHODS:

Eligible patients had EGFR-mutated advanced NSCLC and PD on first-line osimertinib. Patients received oral osimertinib (80 mg once daily) plus intravenous Dato-DXd (4 or 6 mg/kg every 3 weeks). The primary endpoint was investigator-assessed confirmed objective response rate (ORR) per RECIST v1.1. Secondary endpoints were progression-free survival (PFS), duration of response (DoR), overall survival (OS), and safety.

RESULTS:

Sixty-nine patients received study treatment. Among patients in the 4 mg/kg (N = 35) and 6 mg/kg (N = 34) cohorts, respectively, confirmed ORR was 43% [80% confidence interval (CI) 32% to 55%] and 36% (80% CI 25% to 49%); median PFS was 9.5 months (95% CI 7.2-9.8 months) and 11.7 months (95% CI 8.3-21.7 months); median DoR was 6.3 months (95% CI 3.8-8.1 months) and 20.5 months [95% CI 6.2 months-not calculable (NC); estimated median of at least 16 months]; and median OS was 19.8 months (95% CI 13.5-23.3 months) and 26.2 months (95% CI 14.8 months-NC; estimated median greater than or equal to the 4 mg/kg cohort). In the 4 mg/kg and 6 mg/kg cohorts, respectively, grade ≥3 adverse events (AEs) were reported in 49% and 76% of patients; AEs leading to Dato-DXd dose reduction in 23% and 59%; and adjudicated interstitial lung disease/pneumonitis in 3% and 15%.

CONCLUSIONS:

Osimertinib plus Dato-DXd demonstrated clinical benefit in patients with EGFR-mutated advanced NSCLC who progressed on first-line osimertinib. AEs in the 6 mg/kg cohort were of higher frequency and severity but could be managed with prophylaxis, careful monitoring, and dose reduction. The safety profile was consistent with the known profiles of the individual drugs. Considering the overall benefit-risk profile, 6 mg/kg is suggested as the preferred Dato-DXd starting dose for combining with osimertinib 80 mg.

CLINICAL TRIAL NUMBER:

ClinicalTrials.govNCT03944772.

01 Feb 2026·CANCER TREATMENT REVIEWS

Intracranial activity of antibody-drug conjugates in advanced non-small cell lung cancer: What have we accomplished so far?

Review

Author: Remon, Jordi ; Hendriks, Lizza E L ; Huang, Derek De-Rui ; Cheo, Seng Wee ; Saw, Stephanie P L ; Voon, Pei Jye ; Addeo, Alfredo ; Li, Molly S C ; Menis, Jessica

Antibody-drug conjugates (ADCs) represent a rapidly evolving class of therapeutics in non-small cell lung cancer (NSCLC), offering targeted delivery of cytotoxic payloads to tumor cells while minimizing off-target toxicity. Although ADCs have demonstrated promising results in NSCLC, their efficacy in treating central nervous system (CNS) metastases has been uncertain due to concerns over blood-brain barrier (BBB) penetration and the lack of dedicated CNS-specific evaluations in clinical trials. However, emerging evidence challenges this paradigm. While earlier-generation ADCs such as T-DM1 exhibited limited CNS efficacy, newer ADCs employing optimized linkers and cytotoxins demonstrate more favorable efficacy and toxicity profiles. Selected agents, including trastuzumab deruxtecan, datopotamab deruxtecan and patritumab deruxtecan, have all shown intracranial responses in patients with advanced NSCLC with brain metastases (BM). Proposed mechanisms facilitating CNS activity include BBB disruption by BM, membrane-permeable and highly potent cytotoxic payloads, and bystander effects that enable tumor cell killing beyond the target antigen. Nevertheless, several limitations remain, including variability in trial designs, limited number of patients with untreated CNS disease, and a lack of CNS-specific endpoints. Given the high incidence of BM in NSCLC and their significant impact on patient outcomes, there is an urgent need to better understand the intracranial activity of ADCs and whether they can prevent the development of CNS metastases, especially as some of these ADCS are being tested in the curative-intent setting. This review synthesizes current evidence and highlights ongoing trials, with a focused examination of the evolving role of ADCs in the management of BM.

540

News (Medical) associated with Datopotamab Deruxtecan

24 Apr 2026

·www.fiercepharma.com

Daiichi pushes back annual report, citing reviews amid ‘rapidly changing business conditions’

Daiichi Sankyo will unveil its new five-year business plan together with its delayed fiscal year 2025 earnings report on May 11. Daiichi Sankyo has postponed its annual report by two weeks to allow for additional time to finalize the financial figures.The main reason for the delay, according to the Japanese pharma, is the need to review “the supply plans for its oncology products portfolio and development pipeline in light of rapidly changing business conditions.”“As a result, additional deliberation is required to reasonably estimate the amount of loss provisions to be recorded in connection with contracts with contract manufacturers,” the company said in its April 24 announcement (PDF).Daiichi’s shares on the Tokyo Stock Exchange dropped by over 10% following the announcement of the delayed fiscal year earnings results.Simultaneously, Daiichi said it has decided to unveil its new five-year business plan together with its fiscal year 2025 earnings report on May 11 rather than separately on May 19.Daiichi’s annual report will come several weeks after President Donald Trump unveiled a 100% tariff on patented drugs and ingredients. Under existing trade deals, products from the European Union and Japan are subject to a 15% tariff. The administration is also open to offering exemptions under “most favored nation” drug pricing deals, similar to those already signed with 17 large pharmas.Daiichi currently operates two in-house manufacturing facilities in the U.S.—one in Ohio and the other in New York. As part of its global manufacturing expansion plan for its core antibody-drug conjugate business, Daiichi is reportedly investing up to 56 billion yen ($351 million) to build additional facilities at its Ohio campus. The Ohio plant performs fill-finish and packaging duties for ADCs. Additionally, Daiichi produces the monoclonal antibody components of its existing ADCs in the U.S., but not the linker parts of the medicines, Ken Keller, who leads Daiichi’s U.S. branch and its global oncology business, told Fierce during an interview on the sidelines of the J.P. Morgan Healthcare Conference in January.“We feel it’s better for us to look at ways to onshore things, but we’re still developing those plans,” Keller said at the time. Daiichi uses CDMOs as well. The company suffered a setback in 2024 when the FDA rejected its Merck & Co.-partnered HER3 ADC, patritumab deruxtecan (HER3-DXd), because of problems with a contractor’s manufacturing facility. The pair has since withdrawn the application after a phase 3 miss on overall survival in EGFR-mutated non-small cell lung cancer.Besides these factors, the ongoing Iran war is also disrupting the pharmaceutical supply chain by pushing up energy costs and complicating logistics.As of Daiichi’s earnings update in October 2025, the company expected its annual revenue to reach 2,100 billion yen ($13.1 billion), which would represent a 11.3% increase over the previous fiscal year ended in March 2025.By 2030, the company aims to have at least four ADCs on the market, namely AstraZeneca-partnered Enhertu and Datroway, plus HER3-DXd and Merck-partnered CDH6-directed raludotatug deruxtecan. As Enhertu continues to make headway in HER2-positive breast cancer, Datroway faces a pivotal test with the phase 3 Avanzar study in first-line NSCLC, which is expected to read out this year.

ADCPhase 3Financial Statement

22 Apr 2026

·www.prnewswire.com

Actinium Pharmaceuticals, Inc. Announces Compelling Pan-Tumor Data for ATNM-400 Demonstrating Broad Efficacy Across Prostate, Lung, and Breast Cancer Models at the 2026 American Association of Cancer Research Annual Meeting

ATNM-400 demonstrates pan-tumor activity across prostate, lung, and breast cancer models, supporting multi-indication development potential In prostate cancer, ATNM-400 demonstrates efficacy across both high PSMA-expressing and, importantly, low PSMA-expressing prostate cancer models, unlike many PSMA-targeted radioligand therapies that work only in PSMA-high settings In EGFR-mutant non-small cell lung cancer, ATNM-400 demonstrates greater tumor growth inhibition than osimertinib (a tyrosine kinase inhibitor) plus chemotherapy and outperforms the approved Trop-2 ADC Dato-DXd (DATROWAY®), the EGFR-cMET bispecific antibody amivantamab (RYBREVANT®) and the experimental EGFR-HER3 ADC izalontamab brengitecan, supporting potential use across first-, second-, and third-line treatment settings In breast cancer, new head-to-head data shows ATNM-400 achieves efficacy comparable to the approved HER2-ADC trastuzumab deruxtecan (ENHERTU®) in trastuzumab-resistant models, with durable tumor control observed after treatment discontinuation - extending the Company's prior SABCS 2025 data and supporting potential for less frequent dosing of ATNM-400 compared to ADCs ATNM-400 is well tolerated, with no in vivo toxicities observed at efficacious doses, providing a favorable therapeutic index that supports monotherapy and combination development NEW YORK, April 22, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced preclinical results for ATNM-400 across prostate, lung, and breast cancer models presented at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA. ATNM-400 is a novel, first-in-class targeted radiotherapy utilizing the Actinium-225 (Ac-225) radioisotope that targets a non-PSMA membrane antigen overexpressed in advanced and therapy-refractory solid tumors across multiple oncology indications. ATNM-400 is superior to 177Lu-PSMA-617 (Pluvicto) in both high-PSMA (C4-2) and low-PSMA (22Rv1) models, with activity also shown in PSMA-negative (DU145) disease ATNM-400 in EGFR-mutant NSCLC (NCI-H1975) shows head-to-head superiority vs. post-osimertinib SOC and leading ADCs/bispecifics ATNM-400 achieves Enhertu-comparable efficacy in trastuzumab-resistant HER2+ breast cancer (BT474 Clone-5), with durable tumor control after treatment discontinuation

AACRADC

15 Apr 2026

·www.fiercepharma.com

In industry's latest OTC pivot, Daiichi Sankyo lines up $1.5B consumer health unit sale to beverage giant Suntory

Daiichi Sankyo Healthcare markets several popular over-the-counter treatments, such as the decades-old combination cold remedy Lulu and the anti-inflammatory pain and fever reducer Loxonin. With Daiichi Sankyo’s priorities increasingly tied to its innovative medicines—and its oncology portfolio in particular—the Tokyo-based drugmaker is following in the footsteps of several of its peers with a deal to split from its consumer health business. Daiichi has entered an agreement with Japanese beverage giant Suntory Holdings to transfer all shares in its subsidiary, Daiichi Sankyo Healthcare, which markets (PDF) a slate of popular over-the-counter treatments, including the decades-old combination cold remedy Lulu and the anti-inflammatory pain and fever reducer Loxonin. The current deal framework places the transfer value at 246.5 billion Japanese yen (roughly $1.55 billion), Daiichi Sankyo said in an April 15 press release (PDF). As it stands, Daiichi plans to carry out the transfer in stages, starting with the handover of 30% of its consumer health subsidiary’s shares this June. The entire process is expected to wrap up by June 2029, according to the company. Daiichi Sankyo currently holds 100% of the shares in the healthcare unit being sold to Suntory. In its release, Daiichi framed the deal as a means to ensure growth for its over-the-counter drugs business, which has also branched out into areas like skincare, oral care and food products. In turn, Daiichi said that moving forward, it would drill down on its innovative medicines business, and “particularly the oncology business.” Daiichi Sankyo has asserted itself in recent years as a force to be reckoned with among antibody-drug conjugate (ADC) developers, thanks to the success of its two AstraZeneca-partnered products, Enhertu and Datroway. Enhertu has been cleared across breast, gastric and non-small cell lung cancer (NSCLC), plus HER2-positive solid tumors, while Datroway—first approved early last year—is indicated for certain patients with breast cancer and NSCLC. At the J.P. Morgan Healthcare Conference earlier this year, Daiichi CEO Hiroyuki Okuzawa set out the ambition for his company’s ADCs to cover 700,000 eligible patients by fiscal year 2030—an impressive leap from the 120,000 the company tallied for its 2025 fiscal year, which ended in March. Apart from Daiichi, a growing number of drugmakers have elected to part ways with their over-the-counter businesses in recent years. Most recently, Sanofi scooped up 10 billion euros last spring by selling a controlling stake in its consumer health business Opella to U.S. private equity firm Clayton, Dubilier & Rice. Prior to that, prominent consumer health spinouts have been charted by Johnson & Johnson with its Kenvue business and GSK via Haleon, among multiple other recent examples.

Drug ApprovalADCAcquisition

100 Deals associated with Datopotamab Deruxtecan

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB16410

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
EGFR positive non-small cell lung cancer	United States	Daiichi Sankyo, Inc.	23 Jun 2025
ER-positive/HER2-negative Breast Cancer	Australia	AstraZeneca Pty Ltd.	20 May 2025
Advanced Lung Non-Small Cell Carcinoma	Canada	AstraZeneca Canada, Inc.	01 Mar 2025
Hormone receptor positive HER2 negative breast cancer	Japan	Daiichi Sankyo Co., Ltd.	27 Dec 2024

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Triple Negative Breast Cancer	NDA/BLA	United States	AstraZeneca PLC	03 Feb 2025
Triple Negative Breast Cancer	NDA/BLA	United States	Daiichi Sankyo Co., Ltd.	03 Feb 2025
EGFR-mutated non-small Cell Lung Cancer	NDA/BLA	United States	AstraZeneca PLC	12 Nov 2024
EGFR-mutated non-small Cell Lung Cancer	NDA/BLA	United States	Daiichi Sankyo Co., Ltd.	12 Nov 2024
Locally Advanced Lung Non-Squamous Non-Small Cell Carcinoma	NDA/BLA	United States	Daiichi Sankyo, Inc.	19 Feb 2024
Locally Advanced Lung Non-Squamous Non-Small Cell Carcinoma	NDA/BLA	United States	AstraZeneca PLC	19 Feb 2024
Metastatic Non-Squamous Non-Small Cell Lung Carcinoma	NDA/BLA	United States	AstraZeneca PLC	19 Feb 2024
Metastatic Non-Squamous Non-Small Cell Lung Carcinoma	NDA/BLA	United States	Daiichi Sankyo, Inc.	19 Feb 2024
Bladder Cancer	Phase 3	United States	Daiichi Sankyo Co., Ltd.	26 Sep 2025
Bladder Cancer	Phase 3	China	Daiichi Sankyo Co., Ltd.	26 Sep 2025

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03944772 (ORCHARD, ESMO_ELCC2026)	Phase 1	EGFR-mutated non-small Cell Lung Cancer EGFR-mutated	185	Dato-DXd (TROP2 NMR+)	jythbyxgqf(iustdhibqe) = hrajwiuafr phwroqipxd (bdeicbtvqr ) View more	Negative	25 Mar 2026
				Dato-DXd (TROP2 NMR-)	jythbyxgqf(iustdhibqe) = lwgjgeygga phwroqipxd (bdeicbtvqr ) View more
ESMO_ELCC2026	Not Applicable	metastatic non-small cell lung cancer	43	Datopotamab deruxtecan	tmdyavvsya(vlmduepnbb) = tauegeabmt zafejpfuic (quurackdlf ) View more	Positive	25 Mar 2026
ESMO_ELCC2026	Not Applicable	Adenocarcinoma of Lung	56	Datopotamab deruxtecan (Dato-DXd)	jxfvlicvwm(jbcjtplfnl) = Most common reported adverse events were stomatitis (69%, 21% were 3°), keratitis (18%, all were ≤2°), pneumonitis (10%, all were ≤ 2°), and anemia (8%, all were ≤2°). gwpbnsaxes (gbukiorrca ) View more	Positive	25 Mar 2026
				Datopotamab deruxtecan (Dato-DXd) (ECOG PS 0-1)
NCT07129993 (TROPION-Urothelial03, ASCO_GU2026)	Phase 2/3	Metastatic urothelial carcinoma	630	Datopotamab deruxtecan + platinum chemotherapy	mdylhhagap(dsxmakvuyk) = multgcvkpx hiealqyntt (bfbhsjkvdq )	Positive	26 Feb 2026
				Gemcitabine + platinum chemotherapy	atwhyinzar(stosmxkcml) = whmfnhxntv lhbizvdzjt (qstsfjdaqy, 7.7 - 11.3)
NCT05104866 (TROPION-Breast01, CTgov)	Phase 3	Metastatic HER2-Negative Breast Carcinoma	732	Dato-DXd	tsblvyhmxp(nyykcbyymm) = wwkyfjjsno aehvtsqkur (onjkwrjkbj, pkmkecwviy - cxyceofwyu) View more	-	04 Feb 2026
NCT06357533 (TROPION-Lung10, Pubmed \| Front Oncol)	Phase 3	Non-Small Cell Lung Cancer First line PD-L1 expression	675	Datopotamab deruxtecan + Rilvegostomig	oyzxcktdpy(dsombnbogq) = xozbqvvebx vukgjlauyu (glcgfdnguk ) View more	Positive	26 Jan 2026
				Rilvegostomig	oyzxcktdpy(dsombnbogq) = nvboudkpbb vukgjlauyu (glcgfdnguk ) View more
NCT06564844 (TROPION-Lung12, Pubmed \| J Thorac Cardiovasc Surg)	Phase 3	Non-small cell lung cancer stage I Adjuvant ctDNA-positive	660	Datopotamab deruxtecan + Rilvegostomig	qzfrbgbhud(nrrzpfwzky) = ankaxegksr uehgtcmaml (usuniylswe, 30.6 - NR) View more	Positive	01 Jan 2026
				Standard of Care	oorprpqhlm(xmrhjkmacq) = dzydqwkten lecmdjwtsq (adbcpsxsou )
NCT06176261 (DATO-BASE, SABCS 12025 \| SABCS 22025)	Phase 2	HER2-negative breast cancer \| Meningeal Neoplasms HER2-negative	10	Datopotamab deruxtecan (Dato-DXd) 6 mg/kg IV	nyqvdwulbw(wbfnqqoovh) = kuynbeqbge jxcytyqaib (qnscvtbxgx, 0.7 - not reached) View more	Positive	10 Dec 2025
				Datopotamab deruxtecan (Dato-DXd) 6 mg/kg IV (ADC-naïve patients)	nyqvdwulbw(wbfnqqoovh) = sobrskaxpt jxcytyqaib (qnscvtbxgx ) View more
NCT03742102 (BEGONIA, ESMO2025) Manual	Phase 1/2	Triple Negative Breast Cancer First line HER2 Negative \| HR Negative	95	Dato-DXd + durvalumab	nlweewtrno \| zntnoymikc(odefwssizj) = fbdvzvhqaj qbiakvozoe (mosnjonrae, 10.5 - 27.3) View more	Positive	17 Oct 2025
				Dato-DXd + durvalumabDurvalumab (PD-L1-high)	zntnoymikc \| fimgpvomwl(prodvntcvc) = tnfqhvwlfn lysmsedgeq (vrhzcfjwct, 64.5 - 93.0) View more
NCT05374512 (TROPION-Breast02, ESMO2025) Manual	Phase 3	Triple Negative Breast Cancer First line HR Negative \| HER2 Negative	644	Dato-DXd (6 mg/kg IV Q3W)	jcffrimsgc(ixjngevpna) = julvdvmsjs lhwxxwfczp (ekqjbafcok, 19.8 - 25.6) View more	Positive	17 Oct 2025
				Investigator’s choice of chemotherapy (ICC)	jcffrimsgc(ixjngevpna) = qaehgegnyi lhwxxwfczp (ekqjbafcok, 16.0 - 21.8) View more

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.

login

or

view full example data

Understand key drug designations in just a few clicks with Synapse.

Datopotamab Deruxtecan

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Biosimilar

Regulation